Charlotte, North Carolina–(Newsfile Corp. – May 9, 2025) – cbdMD, Inc. (NYSE American: YCBD), one of the nation’s leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Thursday, May 15, 2025, to discuss the company’s March 31, 2025 second quarter of fiscal year 2025 financial results and business progress.
CONFERENCE CALL DETAILS
| Thursday, May 15, 2025, 4:20 p.m. Eastern Time | ||
| USA/Canada: | 833-821-3524 | |
| International: | 647-846-2919 | |
| Teleconference Replay dial in: | ||
| USA/Canada: | 855-669-9658 | |
| International: | 412-317-0088 | |
| Replay Passcode: | 7254091 | |
| Webcast/Webcast Replay link – available through May 15, 2026: | ||
https://www.gowebcasting.com/14065
About cbdMD, Inc.
cbdMD, Inc. (NYSE American: YCBD) is one of the leading and most highly trusted and most recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced THC-free1 CBD products and an array of Farm Act compliant Delta 9 products. Our Paw CBD brand of pet products includes veterinarian-formulated products and our ATRx brand features functional mushroom products. In addition, we operate Herbal Oasis, a premium, award winning THC-infused social seltzer that blends cannabinoids and nootropic mushrooms to deliver a fast-acting, functional beverage made for presence and connection. With an alcohol-free formula and wellness-forward ingredients, Oasis invites a better way to drink-one rooted in clarity, balance, and joy. To learn more about cbdMD and our comprehensive line of U.S. grown, THC-free1 CBD and Full Spectrum products as well as our other brands, please visit www.cbdmd.com, www.pawcbd.com, ATRxlabs.com, or Herbaloasis.com, follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD’s products.
(1) THC-free is defined as below the level of detection using validated scientific analytical methods.
Contact Information:
cbdMD, Inc.
Ronan Kennedy, CEO and CFO
Phone: +1 (704) 445-3064
email: IR@cbdmd.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/251499
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…